Staph sepsis increases mortality in preterm infants

March 12, 2012
Staph sepsis increases mortality in preterm infants

(HealthDay) -- Only about 1 percent of very low birth weight (VLBW) infants develop methicillin-resistant Staphylococcus aureus (MRSA) infections, and the morbidity and mortality are similar to that seen in infants with methicillin-susceptible S. aureus (MSSA) infections, according to a study published online March 12 in Pediatrics.

Andi L. Shane, M.D., M.P.H., from the Emory University School of Medicine in Atlanta, and colleagues analyzed data on morbidity and mortality for 8,444 VLBW infants (birth weight, 401 to 1,500 g), of whom 316 (3.7 percent) had S. aureus bacteremia and/or meningitis.

The researchers found that 88 of the 316 cases (28 percent) were MRSA and 228 cases (72 percent) were MSSA, with no overlap. The two groups were similar in terms of morbidities such as the need for , diagnosis of , and necrotizing enterocolitis. Nearly all (99 percent) of occurred >72 hours after birth. Mortality was high but similar in the resistant and susceptible groups (26 versus 24 percent).

"Few VLBW infants had S. aureus bacteremia and/or meningitis. The 1 percent with MRSA had morbidity and mortality rates similar to infants with MSSA," Shane and colleagues conclude. "Practices should provide equal focus on prevention and management of both MRSA and MSSA infections among VLBW infants."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Recommended for you

The 'love hormone' may quiet tinnitus

September 23, 2016

(HealthDay)—People suffering from chronic ringing in the ears—called tinnitus—may find some relief by spraying the hormone oxytocin in their nose, a small initial study by Brazilian researchers suggests.

Bile acid uptake inhibitor prevents NASH / fatty liver in mice

September 21, 2016

Drugs that interfere with bile acid recycling can prevent several aspects of NASH (nonalcoholic steatohepatitis) in mice fed a high-fat diet, scientists from Emory University School of Medicine and Children's Healthcare of ...

New therapeutic target for Crohn's disease

September 20, 2016

Research from the Sanford Burnham Prebys Medical Discovery Institute (SBP) identifies a promising new target for future drugs to treat inflammatory bowel disease (IBD). The study, published today in Cell Reports, also indicates ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.